SPOTLIGHT: Vertex shares dip on trial schedule


Shares of Vertex Pharmaceuticals slid this morning after the company announced new trials of the hep C drug telaprevir, with full data scheduled for mid-2010. Analysts raised red flags last fall when Vertex reported mixed results from a closely watched mid-stage trial. New trials--needed because of earlier trial design flaws--will delay any final approval, allowing competing therapies from Schering-Plough and Johnson & Johnson to beat Vertex to the market. Release | Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.